Twitter LinkedIn

Pharmaceutical White Collar Posts

OIG 15-Year Exclusion for False Claims Act Violations by Lab Company and its CEO Sends Warning to FCA Defendants
September 13, 2018
By: Carolyn H. Kendall

Eastern District of Pennsylvania Forms Civil Enforcement Strike Force Adding Resources to False Claims Act Cases
August 7, 2018
By: Internal Investigations & White Collar Practice Group

Third Circuit Rejects FCA Claims of Medicare Part D Fraud Applying Post-Escobar Materiality Bar; Acknowledges Validity of Government Knowledge Inference Defense
November 29, 2017
By: Barbara Rowland and Carolyn H. Kendall

Off Label-Marketing and Free Speech: Report from APhA 2017 Annual Meeting
April 5, 2017
By: Matthew T. Newcomer

Government Contests Assertion of Attorney-Client Privilege in Assessing Cooperation
January 5, 2017
By: Ronald H. Levine

Pennsylvania's Medical Marijuana Law, Health Care Providers, and Enforcement
October 13, 2016
By: Barbara Rowland

The Enforceability of FDA's Off-Label Marketing Restrictions Following the Amarin Decision
February 17, 2016
By: Matthew T. Newcomer and Yune D. Emeritz

HHS-OIG Senior Counsel Riordan Focuses on Kickbacks, Accountability, and the Role of Compliance in Pharma Compliance Congress Keynote
October 27, 2015
By: Barbara Rowland

PharMerica Settlements Highlight Potential for Dual False Claims Act and Controlled Substances Act Liability for Invalid Prescriptions
August 29, 2015
The American Society for Pharmacy Law's (ASPL) Rx Ipsa Loquitur
By: Barbara Rowland and Matthew T. Newcomer

Third Circuit Decision Adopts More Lenient Pleading Standard in False Claims Act Litigation
June 24, 2014
By: Barbara Rowland